Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Non-Current Assets (2016 - 2025)

Cytokinetics (CYTK) has disclosed Non-Current Assets for 16 consecutive years, with $507.6 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets changed N/A to $507.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.6 billion through Dec 2025, changed N/A year-over-year, with the annual reading at $507.6 million for FY2025, N/A changed from the prior year.
  • Non-Current Assets for Q4 2025 was $507.6 million at Cytokinetics, up from $459.2 million in the prior quarter.
  • The five-year high for Non-Current Assets was $507.6 million in Q4 2025, with the low at $143.9 million in Q1 2021.
  • Average Non-Current Assets over 5 years is $275.3 million, with a median of $219.6 million recorded in 2022.
  • The sharpest move saw Non-Current Assets soared 497.12% in 2021, then plummeted 42.37% in 2022.
  • Over 5 years, Non-Current Assets stood at $305.6 million in 2021, then decreased by 28.16% to $219.6 million in 2022, then decreased by 10.62% to $196.3 million in 2023, then skyrocketed by 112.7% to $417.5 million in 2024, then increased by 21.58% to $507.6 million in 2025.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $507.6 million, $459.2 million, and $339.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.